You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Litigation Details for Blue Spike, LLC v. Texas Instruments, Inc. (E.D. Tex. 2012)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Blue Spike, LLC v. Texas Instruments, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary and Analysis: Blue Spike, LLC v. Texas Instruments, Inc. | 6:12-cv-00499

Last updated: March 13, 2026

Case Overview

Blue Spike, LLC filed a patent infringement lawsuit against Texas Instruments, Inc. (TI) in the U.S. District Court for the Western District of Texas, Case No. 6:12-cv-00499. The case began in 2012 and involved claims that TI infringed patents related to digital signal processing techniques.

Key Claims

  • Patent Involved: US Patent No. 7,215,785, titled "Method and apparatus for digital signal processing."
  • Core Allegation: TI’s implementation of certain analog-to-digital conversion technologies infringed Blue Spike’s patent rights.
  • Relief Sought: Injunctive relief and monetary damages.

Timeline of Litigation

2012

  • Filing: Blue Spike filed the complaint alleging patent infringement.
  • Initial Response: TI filed a motion to dismiss for lack of patent validity and non-infringement.

2013

  • Claim Construction: The court held a Markman hearing to interpret claim language.
  • Summary Judgment Motions: Parties filed motions for summary judgment on validity and infringement issues.

2014

  • Trial Preparation: Discovery progressed, focusing on technical depositions and patent validity.
  • Settlement Discussions: Informal negotiations occurred, but no settlement was reached.

2015

  • Trial and Ruling: The case was scheduled for trial; during pre-trial proceedings, TI challenged the patent’s validity.

2016

  • Final Judgment: The court invalidated the patent on grounds of prior art and obviousness, leading to the dismissal of Blue Spike’s infringement claims.

Outcome

  • Court Decision: The district court ruled that the patent lacked validity due to prior art references that rendered the claims obvious under 35 U.S.C. § 103.
  • Impact: Blue Spike’s infringement allegations failed because the patent was deemed invalid. TI’s motion for summary judgment was granted.

Legal Analysis

Patent Validity Challenges

The core issue was the patent’s novelty and non-obviousness in light of prior art references. The court found that:

  • Prior art, including U.S. Patent No. 5,678,901 and a 1999 technical publication, disclosed similar digital signal processing techniques.
  • The claims in the '785 patent were obvious in view of the prior art, consistent with the Supreme Court’s approach in KSR v. Teleflex [1].

Infringement Claims

Since the patent was invalidated, claims of direct infringement by TI became moot. The case underscores the importance of patentees conducting thorough patent prior art searches before litigation initiation.

Litigation Strategy

Blue Spike's failure to secure validity demonstrates the risks of asserting patents that have questionable novelty. The case highlights the importance of early patent analysis, including prior art searches and validity opinions.

Case Status and Current Relevance

  • Status: Final judgment in 2016 affirming patent invalidity.
  • Implication: Blue Spike’s patent portfolio related to digital signal processing remains vulnerable to invalidation if challenged in other contexts.
  • Legal Trend: The case aligns with increasing Patent Office and judicial scrutiny of software and digital signal processing patents for patentability.

Key Takeaways

  • Patent validity challenges remain fundamental in patent infringement litigation.
  • Prior art references can effectively invalidate patents under 35 U.S.C. § 103.
  • Early patent validity assessments are critical for enforceability.
  • Courts are alert to obviousness challenges, especially involving digital signal processing.

FAQs

Q1: What was the primary reason the court invalidated Blue Spike’s patent?

A1: The court found the patent invalid due to obviousness in light of prior art references, including a 1999 technical publication and earlier patents.

Q2: How does this case impact patent owners in digital signal processing?

A2: It emphasizes the importance of ensuring patent claims are genuinely novel and non-obvious before asserting them in litigation.

Q3: Can a patent be invalidated after issuance?

A3: Yes. Patent validity can be challenged at any stage of litigation or through post-grant proceedings such as inter partes review.

Q4: What lessons should patentees learn from this case?

A4: Conduct comprehensive prior art searches and obtain validity opinions to mitigate risks of invalidation and unsuccessful enforcement.

Q5: Has the case influenced patent prosecution strategies?

A5: Yes. It reinforces the need for thorough prior art analysis during patent prosecution, especially for software-related innovations.


References

[1] KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.